David C Fisher

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Topics

Histone Deacetylase

Diffuse Large B Cell Lymphoma

Chronic Lymphocytic Leukemia

Top Venues

Dermatologic therapy

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Steven M Horwitz, Ajit J Nirmal, Jahan A Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C Fisher, Neha Mehta-Shah, Youn H Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Mikhaylovna Plotnikova, Valeria Zubareva, Ksenia Zornikova, Nara Shin, Maria A Sorokina, Sandrine Degryse, Ekaterina Postovalova, Aleksander Bagaev, Kinga K Hosszu, Devin McAvoy, Jaap-Jan Boelens, Wenchao Wu, Zoe Ciantra, Jackson W Appelt, Christopher Trevisani, Sam Amaka, David M Weinstock, Santosha A Vardhana
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nature medicine (2024)
Cesar A Virgen, Jeffrey A Sparks, Anju Nohria, Meabh J O'Hare, Amrita Goyal, Jordan T Said, Marianne Tawa, Nicole R LeBoeuf, Thomas S Kupper, David C Fisher, Cecilia Larocca
Mogamulizumab-Associated Myositis With and Without Myasthenia Gravis and/or Myocarditis in Patients With T-Cell Lymphoma. The oncologist (2023)
Christine E Ryan, Danielle M Brander, Paul M Barr, Svitlana Tyekucheva, Liam R Hackett, Mary C Collins, Stacey M Fernandes, Yue Ren, Yinglu Zhou, Mikaela M McDonough, Heather A Walker, Monica R McEwan, Jeremy S Abramson, Eric D Jacobsen, Ann S LaCasce, David C Fisher, Jennifer R Brown, Matthew S Davids
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia (2023)
Jordan T Said, Scott A Elman, Marianne Tawa, David C Fisher, Joseph Frank Merola, Thomas S Kupper
Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement. Dermatologic therapy 35 (7) (2022)